In March 2025, Juventas Cell Therapy Ltd. conducted a phase Ib/II trial to evaluate the safety and efficacy of CNCT19 ...

Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors—a smart fighter that destroys ...

Researchers with City of Hope and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

A bold funding initiative aims to help scientists predict a T cell’s target antigens, with implications far beyond cancer ...

This revolutionary approach has given hope to patients who previously had limited or no options, particularly those battling ...

Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.